ReferenceCitation: Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52.

ReferenceCitation: Seiwert, TC, clement, P. M, Del Campo, J, de Mont-Serrat, H., Thurm, H. C., Blackman, A. S., and Cohen, E. E. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. Journal of Clinical Oncology 28(15 suppl). 2010.

ReferenceCitation: Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44.

ReferenceCitation: Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990 May 15;265(14):7709-12. Review.

ReferenceCitation: Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7. Review.

ReferenceCitation: Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232. Review.

ReferenceCitation: Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993;17F:188-91. Review.

ReferenceCitation: Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol. 2000 Nov 1;18(21 Suppl):54S-9S. Review.

ReferenceCitation: Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol. 1998 Jan;10(1):67-73. Review.

ReferenceCitation: Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000 Feb;6(2):701-8.

ReferenceCitation: Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81. 2006.

ReferenceCitation: Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006 Apr;79(1):15-20. Epub 2006 Apr 17.

ReferenceCitation: Lapeyre M, Henrot P, Alfonsi M, Bardet E, Bensadoun RJ, Dolivet G, Favrel V, Gallocher O, Giraud P, Graff P, Guerif S, Lagarde P, Lartigau E, Marchesi V, Pommier P, Rives M, Tortochaux J, Toussaint B, Verrelle P, Bourhis J, Calais G; Groupe Oncologie Radiothérapie Tête et Cou. [Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded)]. Cancer Radiother. 2005 Jun;9(4):261-70. Epub 2005 Apr 25. Review. French.

ReferenceCitation: Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol. 2003 Dec;69(3):227-36.

ReferenceCitation: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT)(ICRU Report 83) ICRU Report 83, Journal of the ICRU Vol. 10 No. 1. 2011.

ReferenceCitation: Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001 Dec;61(3):275-80.

lead_sponsor: Centre Leon Berard

location_facility: Pôle Hospitalier Mutualiste- Centre Etienne Dolet

location_facility: Institut de Cancérologie de lorraine (ICL)

title: A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02

summary: The purpose of this study is to evaluate the efficacy and safety of Afatinib in maintenance therapy after post-operative radiochemotherapy (66 Gy and Cisplatin at the dose of 100mg/m2 every 3 weeks)in squamous cell carcinoma of the head and neck.


title: Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs

summary: The purpose of this study is to test and validate a new questionnaire in order to get a "walking estimated limitation calculated by history (WELCH) in patients referred for vascular investigations.

status: Unknown status

study_completion_date_type: Anticipated

study_type: Interventional

design_allocation: Non-Randomized

primary_purpose: Diagnostic

enrollment_type: Anticipated

lead_sponsor: University Hospital, Angers

location_facility:
Vascular Medicine
Rehabilitation
Vascular investigation

intervention_type: Other

lead_sponsor_type: academique

status_simplified: Unknown


title: Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour : a Randomised Controlled Trial in Primary Care.

acronym: PIL

summary: To assess the impact of four Patient Information Leaflets (PIL) on patient behaviour in primary care.

status: Completed

study_completion_date_type: Actual

design_allocation: Randomized

primary_purpose: Supportive Care

enrollment_type: Actual

ReferenceType: background

ReferenceCitation: Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, Jordan J. The impact of patient-centered care on outcomes. J Fam Pract. 2000 Sep;49(9):796-804.

ReferenceCitation: Kitching JB. Patient information leaflets--the state of the art. J R Soc Med. 1990 May;83(5):298-300.

ReferenceCitation: Kenny T, Wilson RG, Purves IN, Clark J Sr, Newton LD, Newton DP, Moseley DV. A PIL for every ill? Patient information leaflets (PILs): a review of past, present and future use. Fam Pract. 1998 Oct;15(5):471-9. Review.

ReferenceCitation: Little P, Griffin S, Kelly J, Dickson N, Sadler C. Effect of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial. BMJ. 1998 Jun 27;316(7149):1948-52.

ReferenceCitation: Little P, Dorward M, Warner G, Moore M, Stephens K, Senior J, Kendrick T. Randomised controlled trial of effect of leaflets to empower patients in consultations in primary care. BMJ. 2004 Feb 21;328(7437):441. Epub 2004 Feb 13.

ReferenceCitation: Coudeyre E, Givron P, Vanbiervliet W, Benaïm C, Hérisson C, Pelissier J, Poiraudeau S. [The role of an information booklet or oral information about back pain in reducing disability and fear-avoidance beliefs among patients with subacute and chronic low back pain. A randomized controlled trial in a rehabilitation unit]. Ann Readapt Med Phys. 2006 Nov;49(8):600-8. Epub 2006 May 26. French.

ReferenceCitation: Coudeyre E, Poiraudeau S, Revel M, Kahan A, Drapé JL, Ravaud P. Beneficial effects of information leaflets before spinal steroid injection. Joint Bone Spine. 2002 Dec;69(6):597-603.

ReferenceCitation: McIntosh A, Shaw CF. Barriers to patient information provision in primary care: patients' and general practitioners' experiences and expectations of information for low back pain. Health Expect. 2003 Mar;6(1):19-29.

ReferenceCitation: Watkins CJ, Papacosta AO, Chinn S, Martin J. A randomized controlled trial of an information booklet for hypertensive patients in general practice. J R Coll Gen Pract. 1987 Dec;37(305):548-50.

ReferenceCitation: Roberts L, Little P, Chapman J, Cantrell T, Pickering R, Langridge J. The back home trial: general practitioner-supported leaflets may change back pain behavior. Spine (Phila Pa 1976). 2002 Sep 1;27(17):1821-8.

ReferenceCitation: Johnson LK, Edelman A, Jensen J. Patient satisfaction and the impact of written material about postpartum contraceptive decisions. Am J Obstet Gynecol. 2003 May;188(5):1202-4.

ReferenceCitation: Mancini J, Noguès C, Adenis C, Berthet P, Bonadona V, Chompret A, Coupier I, Eisinger F, Fricker JP, Gauthier-Villars M, Lasset C, Lortholary A, N'Guyen TD, Vennin P, Sobol H, Stoppa-Lyonnet D, Julian-Reynier C. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. Eur J Cancer. 2006 May;42(7):871-81. Epub 2006 Mar 23.

ReferenceCitation: Al-Asfour A, Andersson L. The effect of a leaflet given to parents for first aid measures after tooth avulsion. Dent Traumatol. 2008 Oct;24(5):515-21. doi: 10.1111/j.1600-9657.2008.00651.x.

ReferenceCitation: Carré PC, Roche N, Neukirch F, Radeau T, Perez T, Terrioux P, Ostinelli J, Pouchain D, Huchon G. The effect of an information leaflet upon knowledge and awareness of COPD in potential sufferers. A randomized controlled study. Respiration. 2008;76(1):53-60. doi: 10.1159/000115947. Epub 2008 Feb 5.

ReferenceCitation: Scala D, Cozzolino S, D'Amato G, Cocco G, Sena A, Martucci P, Ferraro E, Mancini AA. Sharing knowledge is the key to success in a patient-physician relationship: how to produce a patient information leaflet on COPD. Monaldi Arch Chest Dis. 2008 Jun;69(2):50-4.

ReferenceCitation: Vetto JT, Dubois PM, Vetto IP. The impact of distribution of a patient-education pamphlet in a multidisciplinary breast clinic. J Cancer Educ. 1996 Fall;11(3):148-52.

ReferenceCitation: Leichtnam-Dugarin L, Carretier J, Delavigne V, Brusco S, Hoarau H, Philip T, Fervers B; Comité d'Organisation des Standards, Options et Recommentations SAVOIR; Fédération Nationale des Centres de lutte contre le cancer; Ligue contre le Cancer; Fédération Hospitalière de France; Fédération Nationale de Cancérologie des CHRU; Fédération Française de Cancérologie. [The SOR SAVOIR Patient, a project of patient information and education]. Cancer Radiother. 2003 Jun;7(3):210-2. French.

ReferenceCitation: Roland M, Dixon M. Randomized controlled trial of an educational booklet for patients presenting with back pain in general practice. J R Coll Gen Pract. 1989 Jun;39(323):244-6.

ReferenceCitation: Macfarlane JT, Holmes WF, Macfarlane RM. Reducing reconsultations for acute lower respiratory tract illness with an information leaflet: a randomized controlled study of patients in primary care. Br J Gen Pract. 1997 Nov;47(424):719-22.

ReferenceCitation: Macfarlane J, Holmes W, Gard P, Thornhill D, Macfarlane R, Hubbard R. Reducing antibiotic use for acute bronchitis in primary care: blinded, randomised controlled trial of patient information leaflet. BMJ. 2002 Jan 12;324(7329):91-4.

ReferenceCitation: Vuorma S, Rissanen P, Aalto AM, Hurskainen R, Kujansuu E, Teperi J. Impact of patient information booklet on treatment decision--a randomized trial among women with heavy menstruation. Health Expect. 2003 Dec;6(4):290-7.

ReferenceCitation: Dedianne MC, Hauzanneau P, Labarere J, Moreau A. Relation médecin-malade en soins primaires: qu'attendent les patients? Investigation par la méthode qualitative des focus groups. La revue du praticien Médecine générale. 2003;17 (612):653-6.

ReferenceCitation: Paul F, Jones MC, Hendry C, Adair PM. The quality of written information for parents regarding the management of a febrile convulsion: a randomized controlled trial. J Clin Nurs. 2007 Dec;16(12):2308-22.

ReferenceCitation: Sustersic M, Voorhoeve M, Menuret H, Baudrant M, Meneau A, Bosson JL. Fiches d'information pour les patients: quel intérêt? L'étude EDIMAP. La Revue de la médecine générale. 2010;276:332-9.

ReferenceCitation: Francis NA, Butler CC, Hood K, Simpson S, Wood F, Nuttall J. Effect of using an interactive booklet about childhood respiratory tract infections in primary care consultations on reconsulting and antibiotic prescribing: a cluster randomised controlled trial. BMJ. 2009 Jul 29;339:b2885. doi: 10.1136/bmj.b2885.

ReferenceCitation: Lerman C, Ross E, Boyce A, Gorchov PM, McLaughlin R, Rimer B, Engstrom P. The impact of mailing psychoeducational materials to women with abnormal mammograms. Am J Public Health. 1992 May;82(5):729-30.

ReferenceType: result

ReferenceCitation: Sustersic M, Meneau A, Drémont R, Paris A, Laborde L, Bosson JL. [Developing patient information sheets in general practice. Proposal for a methodology]. Rev Prat. 2008 Dec 15;58(19 Suppl):17-24. French.

ReferenceCitation: Sustersic M, Meneau A, Drémont R, Paris A, Laborde L, Bosson JL. Elaboration d'un outil d'aide à l'éducation du patient pas la réalisation de 125 fiches d'information et de conseil concernant des motifs de consultation les plus fréquents en médecin générale. Université Joseph Fourier, faculté de médecine de Grenoble. juillet 2007.

lead_sponsor: University Hospital, Grenoble

location_facility:
General practitioner office
University Hospital Grenoble

intervention_type: Procedure

status_simplified: Completed


title: Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy

acronym: ENDOPIK

summary:
This study is to determine the clinical efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line radio chemotherapy.

Clinical efficacy will be determined by the non-progression rate at 3 or 2 months depending on the group of patients. The primary endpoint is the non-progression rate at 3 months (12 weeks) for the patient group whose disease is painless (low grade tumor = stratum 1) and the non-progression rate at 2 months (8 weeks) for the group of patients with an aggressive disease (high grade tumor = stratum 2).

Disease progression is defined by the RECIST 1.1 criteria

primary_purpose: Treatment

lead_sponsor: ARCAGY/ GINECO GROUP

location_facility: Group Hospitalier Mutualiste de Grenoble

intervention_type: Drug

lead_sponsor_type: industriel


title: A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

summary: The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.

ReferenceType: derived

ReferenceCitation: Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

family: Tilly

full_name: Hervé Tilly

given: Hervé

sequence: first

family: Morschhauser

full_name: Franck Morschhauser

given: Franck

sequence: additional

family: Casasnovas

full_name: Olivier Casasnovas

given: Olivier

family: Molina

full_name: Thierry Jo Molina

given: Thierry Jo

family: Feugier

full_name: Pierre Feugier

given: Pierre

family: Gouill

full_name: Steven Le Gouill

given: Steven Le

family: Haioun

full_name: Corinne Haioun

given: Corinne

family: Tournilhac

full_name: Olivier Tournilhac

family: Bouabdallah

full_name: Reda Bouabdallah

given: Reda

family: Gabarre

full_name: Jean Gabarre

given: Jean

family: Lamy

full_name: Thierry Lamy

given: Thierry

family: Cabeçadas

full_name: José Cabeçadas

given: José

family: Becker

full_name: Stéphanie Becker

given: Stéphanie

family: Jardin

full_name: Fabrice Jardin

given: Fabrice

family: Mounier

full_name: Nicolas Mounier

given: Nicolas

family: Salles

full_name: Gilles Salles

given: Gilles

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: The Lancet Haematology

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

ipd_sharing: No

lead_sponsor: The Lymphoma Academic Research Organisation

location_facility:
Hôpital Henri Mondor
Hôpital Necker
Hôpital René Huguenin
Centre Henri BECQUEREL
Hôpital Robert Debré
Institut Curie
Chru Lille
Hôpital Saint Antoine
CHU Estaing
CHU de Poitiers
Chu Brabois
Hôpital Notre Dame de Bon Secours
Polyclinique Bordeaux Nord Aquitaine
Hôpital de la Pitié Salpétrière
Hôpital Saint Eloi
CHU de NANTES
Hôpital St Louis
Institut Paoli Calmettes
Institut Bergonié
Institut Gustave Roussy
Centre Léon Bérard
Hôpital Pontchaillou
Chu Lyon Sud
CHU de DIJON


title: Evaluation of Glucocorticoid Sparing Effect in Patients Receiving RoActemra® for Rheumatoid Arthritis in Real Life.

summary: This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with >5 mg prednisone or equivalent for at least 3 months .

study_type: Observational

time_perspective: Prospective

lead_sponsor: Hoffmann-La Roche


title: Observatoire Prospectif, Longitudinal Dans la Prise en Charge Thérapeutique de La Rectocolite Hémorragique légère à Modérée

acronym: OPTIMUM

summary: The primary objective of this study is to confirm the long-term efficacy (remission and maintenance in remission) of current validated treatments. Each patient will be followed during 3 years in this non-interventional trial.

lead_sponsor: Ferring Pharmaceuticals

location_facility: CH de Bourg-en Bresse Hopital de Fleyriart (Viriat)

location_facility: Centre Hospitalier du Haut Anjou Hospital St Julien

location_facility: Groupe Hospitalier Mutualiste "Les Portes du Sud"

location_facility: Groupe Hospitalier Mutualiste Les Portes du Sud

location_facility: Centre Hospitalier Departemental Les Oudairies

location_facility: Centre Hospitalier de Tourcoing-Hôpital DRON


title: Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer

summary: GYNECO 02 hypothesis is that hysterectomy reduces the possibility of local or loco-regional relapse, especially in patient with a reduced metastatic risk and who received a local chemoradiation therapy with an increase of radiotherapy doses (45 grays).

status: Terminated

lead_sponsor: UNICANCER

location_facility: Clinique Sainte Thérèse de l'enfant Jésus

location_facility: Centre Hospitalier Universitaire Jean Bernard

location_facility: Centre Hospitalier Universitaire - Hôpital Arnaud de Villeneuve

location_facility: Centre Hospitalier Régional Universitaire La Timone

location_facility: Centre Hospitalier Universitaire de Brest

location_facility: Centre Universitaire Hospitalier- Hôpital Sud

location_facility: Centre Hospitalier Régional Universitaire Hôpital Nord


title: National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients

acronym: CARMEN

summary: Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.

ReferenceCitation: Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007 Nov 15;110(10):2339-46.

ReferenceCitation: Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91.

ReferenceCitation: Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005 Dec 15;104(12):2822-9.

ReferenceCitation: Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006 Mar;4(3):529-35.

ReferenceCitation: Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 Feb 27;166(4):458-64.

ReferenceCitation: Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15.

ReferenceCitation: Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006 Mar 20;24(9):1404-8.

lead_sponsor: Floralis

location_facility: Centre Régional de Lutte Contre le Cancer Val d'Aurelle

location_facility: Centre de Lutte contre le Cancer (Centre René Gauducheau)

location_facility: Centre Hospitalier Mutualiste Site Etienne Dolet

location_facility: Centre Hospitalier de Villefranche sur Saône


title: Patients Presenting With Acute STEMI Treated With Primary PCI : Comparison of the Impact of the MIMI Approach With a Conventional Strategy of Immediate Stenting

acronym: MIMI

summary: In the setting of primary Percutaneous Coronary Intervention (PCI), the investigators hypothesize that a 24-48 hour delay strategy of stenting after successful thrombus aspiration and establishment of Thrombolysis In Myocardial Infarction (TIMI)-3 flow with optimal antithrombotic therapy may decrease the risk of MicroVascular Obstruction (MVO) as assessed by Cardiac Magnetic Resonance Imaging (CMRI).

ReferenceCitation: Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991 Aug 15;115(4):256-65.

ReferenceCitation: Brodie BR, Stuckey TD, Hansen C, VerSteeg DS, Muncy DB, Moore S, Gupta N, Downey WE. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005 Feb 1;95(3):343-8.

ReferenceCitation: Bruder O, Breuckmann F, Jensen C, Jochims M, Naber CK, Barkhausen J, Erbel R, Sabin GV; Herzinfarktverbund Essen. Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen". Herz. 2008 Mar;33(2):136-42. doi: 10.1007/s00059-008-3102-8.

ReferenceCitation: Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, Wöhrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005 Mar;26(6):549-57. Epub 2005 Feb 15.

ReferenceCitation: Isaaz K, Robin C, Cerisier A, Lamaud M, Richard L, Da Costa A, Sabry MH, Gerenton C, Blanc JL. A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coron Artery Dis. 2006 May;17(3):261-9.

ReferenceCitation: Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009 Dec 1;120(22):2271-306. doi: 10.1161/CIRCULATIONAHA.109.192663. Epub 2009 Nov 18. Erratum in: Circulation. 2010 Mar 30;121(12):e257. Dosage error in article text.

ReferenceCitation: Meneveau N, Séronde MF, Descotes-Genon V, Dutheil J, Chopard R, Ecarnot F, Briand F, Bernard Y, Schiele F, Bassand JP. Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients. Clin Res Cardiol. 2009 Apr;98(4):257-64. doi: 10.1007/s00392-009-0756-z. Epub 2009 Feb 9.

ReferenceCitation: Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008 Jul 15;52(3):181-9. doi: 10.1016/j.jacc.2008.04.006.

ReferenceCitation: Sardella G, Mancone M, Bucciarelli-Ducci C, Agati L, Scardala R, Carbone I, Francone M, Di Roma A, Benedetti G, Conti G, Fedele F. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009 Jan 27;53(4):309-15. doi: 10.1016/j.jacc.2008.10.017.

ReferenceCitation: Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. Epub 2007 Jul 30.

ReferenceCitation: Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008 Feb 7;358(6):557-67. doi: 10.1056/NEJMoa0706416.

ReferenceCitation: Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

ReferenceCitation: Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12.

ReferenceCitation: Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998 Mar 3;97(8):765-72.

ReferenceCitation: Belle L, Motreff P, Mangin L, Rangé G, Marcaggi X, Marie A, Ferrier N, Dubreuil O, Zemour G, Souteyrand G, Caussin C, Amabile N, Isaaz K, Dauphin R, Koning R, Robin C, Faurie B, Bonello L, Champin S, Delhaye C, Cuilleret F, Mewton N, Genty C, Viallon M, Bosson JL, Croisille P; MIMI Investigators*. Comparison of Immediate With Delayed Stenting Using the Minimalist Immediate Mechanical Intervention Approach in Acute ST-Segment-Elevation Myocardial Infarction: The MIMI Study. Circ Cardiovasc Interv. 2016 Mar;9(3):e003388. doi: 10.1161/CIRCINTERVENTIONS.115.003388.

name: From the Departments of Cardiology and Radiology, Centre Hospitalier Annecy-Genevois, Annecy, France (L. Belle, L.M., A.M.); Department of Cardiology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France (P.M., G.S.); Department of Cardiology, Les Hôpitaux de Chartres, Eure-et-Loir, France (G.R.); Department of Cardiology, Centre Hospitalier de Vichy, Vichy, France (X.M., N.F.); Department of Cardiology, Centre Hospitalier St Luc St Joseph, Lyon, France (O.D.); Department of Cardiology,...

family: Belle

full_name: Loic Belle

given: Loic

family: Motreff

full_name: Pascal Motreff

given: Pascal

family: Mangin

full_name: Lionel Mangin

given: Lionel

family: Rangé

full_name: Grégoire Rangé

given: Grégoire

family: Marcaggi

full_name: Xavier Marcaggi

given: Xavier

family: Marie

full_name: Antoine Marie

given: Antoine

family: Ferrier

full_name: Nadine Ferrier

given: Nadine

family: Dubreuil

full_name: Olivier Dubreuil

family: Zemour

full_name: Gilles Zemour

family: Souteyrand

full_name: Géraud Souteyrand

given: Géraud

family: Caussin

full_name: Christophe Caussin

given: Christophe

family: Amabile

full_name: Nicolas Amabile

family: Isaaz

full_name: Karl Isaaz

given: Karl

family: Dauphin

full_name: Raphael Dauphin

given: Raphael

family: Koning

full_name: René Koning

given: René

family: Robin

full_name: Christophe Robin

family: Faurie

full_name: Benjamin Faurie

given: Benjamin

family: Bonello

full_name: Laurent Bonello

given: Laurent

family: Champin

full_name: Stanislas Champin

given: Stanislas

family: Delhaye

full_name: Cédric Delhaye

publisher: Ovid Technologies (Wolters Kluwer Health)

title: Comparison of Immediate With Delayed Stenting Using the Minimalist Immediate Mechanical Intervention Approach in Acute ST-Segment–Elevation Myocardial Infarction

location_facility:
Clinique du Tonkin
CH
Clinique St Hilaire
CHU Croix Rousse
CHI
Clinique Marie Lannelongue
Clinique de Courlancy
Clinique St Gatien
CH St Luc St Joseph
Hopital Privé
Clinique Convert
Clinique Mutualiste
CHU Nord
Ch Bastia
CHU
CHRA


title: Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

acronym: RITUX-ERAH

summary: Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"

lead_sponsor: University Hospital, Tours

location_facility:
Hospital Bretonneau
Hospital Maison Blanche
Hospital Hôtel Dieu
Hospital Saint-Jacques
Hospital Lapeyronie
Hospital Dupuytren
Hospital Edouard Herriot
Hospital Lyon Sud
Hospital Bois-Guillaume
Hospital Bocage
Hospital Pitié-Salpêtrière
Hospital Saint Louis
Hospital Calmette
Hospital Pasteur
Hospital Pellegrin
Hospital Sud
Hospital Henri Mondor
Hospital Conception
Hospital Gabriel Montpied
Hospital Bicêtre
Hospital Civil
Hospital Nord
Hospital Tenon
Hospital
Hospital Milétrie Jean Bernard
Hospital Necker


title: Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

acronym: TARSEQ

summary:
This 2 arms study will compare the efficacy and safety of treatment with sequential erlotinib plus docetaxel therapy versus docetaxel alone as second line treatment in patients with recurrent non-small cell lung cancer. Patients will be randomized to receive in group 1(experimental arm): docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16 and group 2 (control arm): docetaxel :75 mg/m² IV day 1 every 3 weeks.

The anticipated time on study treatment is until disease progression. Target sample size is 156.

The main of this study is to determine the relevance of the association sequential erlotinib and docetaxel in terms of progression-free survival .

lead_sponsor: University Hospital, Limoges

location_facility: Service de Pneumologie, Hôpital de la Croix Rousse

location_facility: Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay

location_facility: Clinique Pneumologique; Hôpital Charles Nicolle

location_facility: Service de pneumologie; Centre Hospitalier d'Annecy

location_facility: Hôpital Charles Nicolle, Service de Pneumologie

location_facility: Service de Pneumologie; Hôpital Bois Guillaume

location_facility: Service de Pneumologie, Hôpital Pontchailloux

location_facility: Service de Pneumologie ; Centre hospitalier

location_facility: Service de Pneumologie - Hôpital St Antoine, Paris

location_facility: Service de Pneumologie; Centre Hospitalier

location_facility: Département des Maladies Respiratoires ; Hôpital Sainte Marguerite

location_facility: Département de Pathologie Respiratoire du CHU de Limoges

location_facility: Service de Pneumologie-Allergologie; Centre Hospitalier Général


title: A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.

summary: This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.


type: Registry Identifier

title: ORM Narval Mandibular Repositioning Device in the Second-line Treatment of Severe OSAH

acronym: ORCADES

summary: The purpose of this study is to evaluate the long-term efficacy, tolerance and compliance of ORM Narval Mandibular Repositioning Device (MRD) as a second-line treatment for patients with severe Obstructive Sleep Apnea Hypopnea (OSAH) syndrome who refuse or are intolerant to Continuous Positive Airway Pressure (CPAP) treatment.

study_start_date_type: Actual

ReferenceCitation: Vecchierini MF, Attali V, Collet JM, d'Ortho MP, El Chater P, Kerbrat JB, Leger D, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Meurice JC; ORCADES investigators. A custom-made mandibular repositioning device for obstructive sleep apnoea-hypopnoea syndrome: the ORCADES study. Sleep Med. 2016 Mar;19:131-40. doi: 10.1016/j.sleep.2015.05.020. Epub 2015 Jun 29.

family: Vecchierini

full_name: Marie-Françoise Vecchierini

given: Marie-Françoise

family: Attali

full_name: Valérie Attali

given: Valérie

family: Collet

full_name: Jean-Marc Collet

given: Jean-Marc

family: d'Ortho

full_name: Marie-Pia d'Ortho

given: Marie-Pia

family: El Chater

full_name: Pierre El Chater

given: Pierre

family: Kerbrat

full_name: Jean-Baptiste Kerbrat

given: Jean-Baptiste

family: Leger

full_name: Damien Leger

given: Damien

family: Monaca

full_name: Christelle Monaca

given: Christelle

family: Monteyrol

full_name: Pierre-Jean Monteyrol

given: Pierre-Jean

family: Morin

full_name: Laurent Morin

family: Mullens

full_name: Eric Mullens

given: Eric

family: Pigearias

full_name: Bernard Pigearias

given: Bernard

family: Meurice

full_name: Jean-Claude Meurice

given: Jean-Claude

journal_name: Sleep Medicine

oa_host_type: publisher

evidence: open (via crossref license)

host_type: publisher

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

version: publishedVersion

title: A custom-made mandibular repositioning device for obstructive sleep apnoea–hypopnoea syndrome: the ORCADES study

ReferenceCitation: Attali V, Vecchierini MF, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Tordjman F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators. Efficacy and tolerability of a custom-made Narval mandibular repositioning device for the treatment of obstructive sleep apnea: ORCADES study 2-year follow-up data. Sleep Med. 2019 Nov;63:64-74. doi: 10.1016/j.sleep.2019.04.021. Epub 2019 Jun 12.

family: Goutorbe

full_name: Frederic Goutorbe

given: Frederic

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

ReferenceCitation: Vecchierini MF, Attali V, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators, Abedipour D, Allard-Redon A, Aranda A, Attali V, Bavozet F, Becu M, Beruben W, Bessard J, Bonafe I, Boukhana M, Chabrol B, Chatte G, Lebret C, Collet JM, Coste O, Dumont N, Durand-Amat S, D'ortho MP, Elbaum JM, De Santerre OG, Goutorbes F, Grandjean T, Guyot W, Hammer D, Havasi C, Huet P, Kerbrat JB, Khemliche H, Koltes C, Leger D, Lacassagne L, Laur X, Lerousseau L, Liard O, Loisel C, Longuet M, Mallart A, Martin F, Merle Beral F, Meurice JC, Mokhtari Z, Monaca C, Monteyrol PJ, Muir JF, Mullens E, Muller D, Paoli C, Petit FX, Pigearias B, Pradines M, Prigent A, Putterman G, Rey M, Samama M, Tamisier R, Tiberge M, Tison C, Tordjman F, Triolet B, Vacher C, Vecchierini MF, Verain A. Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome. Sleep Breath. 2019 Sep;23(3):837-848. doi: 10.1007/s11325-018-1766-8. Epub 2018 Dec 22.

location_facility: Fondation Bon Sauveur / cabinet médical / cabinet dentaire

location_facility: CHRU Montpellier / Clinique Beau Soleil / Faculté d'Odontologie / cabinet dentaire

location_facility: CH Compiègne Senlis / cabinets dentaires

location_facility: Maison de la Mutualité / polyclinique de l'Atlantique

location_facility: CHRU Rennes / polyclinique St Laurent / cabinet dentaire

location_facility: Polyclinique du Tondu / cabinet dentaire

location_facility: Centre Médical Plateau de Haye / cabinet médical / cabinet dentaire


type: Other Identifier

title: Complications Associated With Promontofixation for Pelvic Organ Prolapse: a Randomized Trial Comparing Robot Assisted Laparoscopic and Non-robot Assisted Laparoscopic Surgical Procedures

acronym: RoboLaps

summary: The primary objective of this study is to compare 30-day complication rates associated with promontofixation for pelvic organ prolapse performed via a robot-assisted laparoscopic technique versus a non-robot-assisted laparoscopic technique. Secondary objectives include comparing technical data, anatomical correction, prolapse recurrence, incontinence, quality of life and medico-economic data between the two techniques.

status: Active, not recruiting

lead_sponsor: Centre Hospitalier Universitaire de Nīmes

location_facility: Groupe Hospitalier Diaconesses Croix Saint-Simon - Site Reuilly

location_facility: APHP - Groupe Hospitalier Pitié-Salpetrière

location_facility: CHU de Nîmes - Hôpital Universitaire Carémeau

location_facility: CHU de Lyon - Centre Hospitalier Lyon Sud

status_simplified: Ongoing


lead_sponsor: Novartis Pharmaceuticals

acronym: LUDIC

type: EudraCT Number

source: euctr

title: An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice

summary: The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.


title: Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts

summary:
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Observation is watching a patient's condition but not giving treatment until symptoms appear. It is not yet known whether giving gemcitabine hydrochloride together with oxaliplatin is more effective than observation in treating patients with biliary tract cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying giving gemcitabine hydrochloride together with oxaliplatin to see how well it works compared with observation in treating patients with biliary tract cancer that has been removed by surgery.

location_facility:
Hôpital Edouard Herriot
Hôpital Nord
Hôpital Henri Mondor
Centre hospitalier de la Côte Basque
CHU Saint Louis
Centre Paul Papin
Hôpital La Source
Hôpital Jean Minjoz
Centre René Gauducheau
CHU Brest - Hôpital Morvan
Hôpital Beaujon
CHU Sainte-Etienne - Hopital Nord
CHU Timone Adulte
Hôpital Saint Antoine
Hôpital Trousseau
CHU Estaing
CHU de Poitiers
CHU Brabois
Hôpital Privé Jean Mermoz
Hôpital de Hautepierre / Hôpital Civil
Hôpital de la Pitié Salpétrière
CHU Côte de Nacre
Centre Eugene Marquis
Hôpital Européen Georges Pompidou
Hôpital Bocage
CHU - Hôpital Nord
Hôpital Saint Joseph
Centre Paul Strauss
Institut Paoli Calmettes
Hôpital Avicenne
CHD Vendée
CHU de Rouen - Hôpital Ch. Nicolle
Institut Gustave Roussy
Institut Mutualiste Montsouris
Centre Léon Bérard
Institut Sainte Catherine
Centre Hospitalier Saint Eloi


title: A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients

summary: A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients.

lead_sponsor: Groupe Francophone des Myelodysplasies

location_facility: CHU Albert Michallon - Service d'Hématologie Clinique

location_facility: Hopital Saint Louis - AP-HP, Hematology Dpt

location_facility: Hopital Purpan Service d'Hématologie Clinique


title: A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

summary:
Patients will receive escalating doses of ldarubicin combined to Azacitidine given at the FDA/EMEA approved Schedule and dosing.

For the Phase I study :

Determine the safety and tolerance of escalating doses of Idarubicin combined to Azacitidine in patients with INT-2 or higher risk MDS.

For the phase II study:

Primary: Evaluate rate and duration of response (according to IWG 2006 criteria and IWG 2000 criteria) to the combination of Idarubicin and Azacitidine in patients with INT-2 or higher risk MDS

location_country: Tunisia France

location_facility: Hôpital Saint Louis - Hématologie Séniors

location_facility: Hôpital saint louis - Hématologie Clinique


title: Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort.

summary: The purpose of this study is to evaluate the impact of thromboembolic diseases and heparin complications in patients with a lower limb trauma supported by physicians of mountain.

ReferenceCitation: Motykie GD, Zebala LP, Caprini JA, Lee CE, Arcelus JI, Reyna JJ, Cohen EB. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis. 2000 Apr;9(3):253-62. Review.

ReferenceCitation: Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S4-13. Review.

ReferenceCitation: Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol. 2010 Jun;149(6):824-33. doi: 10.1111/j.1365-2141.2010.08206.x. Epub 2010 Apr 29. Review.

ReferenceCitation: Gensini GF, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost. 1997;23(1):55-67. Review.

ReferenceCitation: Eschwège V, Robert A. Strikes in French public transport and resistance to activated protein C. Lancet. 1996 Jan 20;347(8995):206.

ReferenceCitation: Vaitkus PT, Leizorovicz A, Goldhaber SZ; PREVENT Investigator Group. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med. 2002;7(4):269-73.

ReferenceCitation: Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006 Feb 11;332(7537):325-9. Epub 2006 Jan 26.

ReferenceCitation: Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Haemostasis. 1993 Mar;23 Suppl 1:20-6.

ReferenceCitation: Jørgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R, Kirchhoff-Jensen R, Kjaer L, Kerbouche N, Leth-Espensen P, Narvestad E, Rasmussen SW, Sloth C, Tørholm C, Wille-Jørgensen P. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res. 2002 Mar 15;105(6):477-80.

ReferenceCitation: Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002 Sep 5;347(10):726-30.

ReferenceCitation: Riou B, Rothmann C, Lecoules N, Bouvat E, Bosson JL, Ravaud P, Samama CM, Hamadouche M. Incidence and risk factors for venous thromboembolism in patients with nonsurgical isolated lower limb injuries. Am J Emerg Med. 2007 Jun;25(5):502-8.

location_facility: Medical group "SELARL Sports médecine montagne"

location_facility: Medical center of Beauregard - "les cyclamens"


title: Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma

acronym: TACERTE

summary: Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose total tumor mass can technically be irradiated, non-resectable, and not a candidate for percutaneous therapy with recommended treatment via hyperselective transarterial chemoembolisation (TACE).

lead_sponsor: Nantes University Hospital

location_facility:
AP-HP Paul Brousse Villejuif
Centre Eugene Marquis
CHU de Reims
Hôpital Tenon
CHU d'Angers
CHU de Bordeaux
CHD les Oudairies
AP-HP Henri Mondor
CHU de Nancy Hôpital Brabois
CHU Amiens
CHR Orléans
CHR de Lille Hôpital Claude Huriez
CHU Dijon
Institut Sainte Catherine
CHU de Lyon
CHU Nantes
La Pitié-Salpétrière
CH Avignon


title: A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis

acronym: SPARSE

summary: This study will compare the Non Steroidal Anti-Inflammatory Drugs (NSAIDs) sparing effect of etanercept with that of placebo in adult subjects with axial Spondyloarthritis.

ReferenceCitation: Dougados M, Wood E, Gossec L, Dubanchet A, Logeart I, van der Heijde D. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. J Rheumatol. 2015 Dec;42(12):2361-8. doi: 10.3899/jrheum.150378. Epub 2015 Nov 15.

family: Dougados

full_name: Maxime Dougados

given: Maxime

family: Wood

full_name: Emily Wood

given: Emily

family: Gossec

full_name: Laure Gossec

given: Laure

family: Dubanchet

full_name: Arnaud Dubanchet

given: Arnaud

family: Logeart

full_name: Isabelle Logeart

given: Isabelle

family: van der Heijde

full_name: Désirée van der Heijde

given: Désirée

journal_name: The Journal of Rheumatology

publisher: The Journal of Rheumatology

publisher_dissemination: The Journal of Rheumatology

publisher_group: The Journal of Rheumatology

publisher_normalized: The Journal of Rheumatology

ReferenceCitation: Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli-Richard C, Berenbaum F, Koppiker N, Dubanchet A, Logeart I. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther. 2014 Nov 27;16(6):481. doi: 10.1186/s13075-014-0481-5.

family: Combe

full_name: Bernard Combe

family: Schaeverbeke

full_name: Thierry Schaeverbeke

given: Thierry

family: Miceli-Richard

full_name: Corinne Miceli-Richard

given: Corinne

family: Berenbaum

full_name: Francis Berenbaum

given: Francis

family: Koppiker

full_name: Nandan Koppiker

given: Nandan

currency_apc_doaj: GBP

journal_name: Arthritis Research & Therapy

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Archive ouverte HAL

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

location_facility: Hopital Saint Joseph - Service de Rhumatologie

location_facility: CHU Bois Guillaume - Service de Rhumatologie

location_facility: Centre Hospitalier, Service de Rhumatologie

location_facility: Chu Dupuytren, Rhumatologie et Therapeutique


title: Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi

acronym: CAMOMY

summary: The purpose of this study is to determine the 6-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary infection.

ReferenceCitation: TIMPE A, RUNYON EH. The relationship of atypical acid-fast bacteria to human disease; a preliminary report. J Lab Clin Med. 1954 Aug;44(2):202-9.

ReferenceCitation: RUNYON EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959 Jan;43(1):273-90.

ReferenceCitation: Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. Review. Erratum in: Am J Respir Crit Care Med. 2007 Apr 1;175(7):744-5. Dosage error in article text.

ReferenceCitation: Falkinham JO 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med. 2002 Sep;23(3):529-51. Review.

ReferenceCitation: von Reyn CF, Waddell RD, Eaton T, Arbeit RD, Maslow JN, Barber TW, Brindle RJ, Gilks CF, Lumio J, Lähdevirta J, et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J Clin Microbiol. 1993 Dec;31(12):3227-30.

ReferenceCitation: Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax. 1983 May;38(5):373-7.

ReferenceCitation: Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax. 1984 May;39(5):376-82.

ReferenceCitation: American Thoracic Society. Diagnosis standards and classification of tuberculosis and other mycobacterial diseases. New York: American Lung Association, 1974:25

ReferenceCitation: Wallace RJ, O'Brien R, Glassroth J, Raleigh J, Dutt A. American Thoracic Society. Diagnosis and treatment of disease caused by non tuberculous mycobacteria. Am Rev Respir Dis 142:940-53, 1990

ReferenceCitation: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 2):S1-25. Review.

ReferenceCitation: Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 2000 Mar;55(3):210-8.

ReferenceCitation: Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, Lozniewski A, Maugein J; French Mycobacteria Study Group. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J. 2006 Dec;28(6):1211-5.

ReferenceCitation: Jenkins PA, Campbell IA; Research Committee of The British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med. 2003 Apr;97(4):439-44.

ReferenceCitation: Baugnée PE, Pouthier F, Delaunois L. [Pulmonary mycobacteriosis due to Mycobacterium xenopi" in-vitro sensitivity to classical antitubercular agents and clinical development]. Acta Clin Belg. 1996;51(1):19-27. French.

ReferenceCitation: Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsch-Gerdes S, Tortoli E, Vincent V, Watt B; Spanish Group for Non-Tuberculosis Mycobacteria. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis. 2004 Oct;8(10):1186-93.

ReferenceCitation: Yates MD, Pozniak A, Uttley AH, Clarke R, Grange JM. Isolation of environmental mycobacteria from clinical specimens in south-east England: 1973-1993. Int J Tuberc Lung Dis. 1997 Feb;1(1):75-80.

ReferenceCitation: Andréjak C, Lescure FX, Douadi Y, Laurans G, Smail A, Duhaut P, Jounieaux V, Schmit JL. Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect. 2007 Jul;55(1):34-40. Epub 2007 Mar 13.

ReferenceCitation: Andréjak C, Lescure FX, Pukenyte E, Douadi Y, Yazdanpanah Y, Laurans G, Schmit JL, Jounieaux V; Xenopi Group. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. 2009 Apr;64(4):291-6. doi: 10.1136/thx.2008.096842. Epub 2008 Dec 3.

ReferenceCitation: Costrini AM, Mahler DA, Gross WM, Hawkins JE, Yesner R, D'Esopo ND. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis. 1981 Jan;123(1):104-9.

ReferenceCitation: Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, Sørensen HT, Lescure FX, Thomsen RW. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010 Mar 1;181(5):514-21. doi: 10.1164/rccm.200905-0778OC. Epub 2009 Dec 10.

ReferenceCitation: Dautzenberg B, Papillon F, Lepitre M, Truffot-Pernod C, Chauvin JP. Mycobacterium xenopi infections treated with clarithromycine-containing regimens. Annual meeting, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy.

ReferenceCitation: Alfandari S. Recommandations du C-CLIN Paris Nord pour le diagnostic et le traitement des infections ostéo-articulaires à Mycobacterium xenopi. Med Mal Infect 28 :231-234, 1998.

ReferenceCitation: Klemens SP, Cynamon MH. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother. 1994 Jul;38(7):1455-9.

ReferenceCitation: Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother. 2001 Nov;45(11):3229-30.

ReferenceCitation: Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008 Jul;63(7):627-34. doi: 10.1136/thx.2007.087999. Epub 2008 Feb 4. Erratum in: Thorax. 2008 Sep;63(9):844.

ReferenceCitation: Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. 2009 Oct;13(10):1210-8. Review.

ReferenceCitation: Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1766-72.

ReferenceCitation: Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995 Apr;107(4):1035-40.

ReferenceCitation: Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000 Feb;30(2):288-92.

ReferenceCitation: Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis. 1996 Nov;23(5):983-9.

ReferenceCitation: Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999 Sep;160(3):866-72.

ReferenceCitation: Dauendorffer JN, Laurain C, Weber M, Dailloux M. In vitro sensitivity of Mycobacterium xenopi to five antibiotics. Pathol Biol (Paris). 2002 Dec;50(10):591-4.

ReferenceCitation: Berlin OG, Young LS, Floyd-Reising SA, Bruckner DA. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria. Eur J Clin Microbiol. 1987 Aug;6(4):486-7.

ReferenceCitation: Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother. 1991 Feb;27 Suppl A:61-5.

ReferenceCitation: Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):215-21.

ReferenceCitation: Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999 Sep;44(3):393-5.

ReferenceCitation: Alcaide F, Calatayud L, Santín M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004 Dec;48(12):4562-5.

ReferenceCitation: Rodriguez Díaz JC, López M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents. 2003 Jun;21(6):585-8.

ReferenceCitation: Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003 Dec 1;168(11):1342-5. Epub 2003 Aug 13.

ReferenceCitation: Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis. 2003 Jun 15;187(12):1977-80. Epub 2003 Jun 4.

ReferenceCitation: Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother. 2001 Jan;45(1):217-22.

ReferenceCitation: Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2003 Oct;47(10):3117-22.

ReferenceCitation: Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother. 2003 Feb;15(1):66-70.

ReferenceCitation: Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99. Review.

ReferenceCitation: Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007 Feb;51(2):576-82. Epub 2006 Dec 4.

ReferenceCitation: Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998 Feb;113(2):272-7.

ReferenceCitation: Bégaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985 Mar-Apr;40(2):111-8. French.

ReferenceCitation: Rhodes VA, McDaniel RW. The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. Oncol Nurs Forum. 1999 Jun;26(5):889-94.

lead_sponsor: Centre Hospitalier Universitaire, Amiens

location_facility: Centre National de Reference Des Mycobactéries

location_facility: CHU Montpellier Hôpital Arnaud de Villeneuve

location_facility: Assistance Publique Hôpitaux de Paris, hôpital TENON

location_facility: Assistance Publique Hôpitaux de Marseille

location_facility: Assistance Publique Hôpitaux de Paris Hôpital Saint Antoine

location_facility: Assistance Publique Hôpitaux de Paris CHU Avicenne

location_facility: CHU Clermont Ferrand Hôpital Gabriel Mont pied

location_facility: Assistance Publique Hôpitaux de Paris Hôpital BICHAT

location_facility: Assistance Publique Hôpitaux de Paris Hôpital Saint Louis

location_facility: Assistance Publique Hôpitaux de Paris Hôpital Bicetre


type: Other Grant/Funding Number

title: Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?

summary: The purpose of this study is to estimate the sensibility at the growth hormone in vivo at the children presenting a Prader-Willi syndrome (SPW) in comparison with children presenting a deficit in growth hormone (GHD).

ReferenceCitation: Cadoudal T, Buléon M, Sengenès C, Diene G, Desneulin F, Molinas C, Eddiry S, Conte-Auriol F, Daviaud D, Martin PG, Bouloumié A, Salles JP, Tauber M, Valet P. Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment. Int J Obes (Lond). 2014 Sep;38(9):1234-40. doi: 10.1038/ijo.2014.3. Epub 2014 Jan 10.

family: Cadoudal

full_name: T Cadoudal

given: T

family: Buléon

full_name: M Buléon

given: M

family: Sengenès

full_name: C Sengenès

given: C

family: Diene

full_name: G Diene

given: G

family: Desneulin

full_name: F Desneulin

given: F

family: Molinas

full_name: C Molinas

family: Eddiry

full_name: S Eddiry

given: S

family: Conte-Auriol

full_name: F Conte-Auriol

family: Daviaud

full_name: D Daviaud

given: D

family: Martin

full_name: P G P Martin

given: P G P

family: Bouloumié

full_name: A Bouloumié

given: A

family: Salles

full_name: J-P Salles

given: J-P

family: Tauber

full_name: M Tauber

family: Valet

full_name: P Valet

given: P

journal_name: International Journal of Obesity

evidence: open (via free pdf)

license_normalized: no license

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer

publisher_group: Springer

publisher_normalized: Springer

title: Impairment of adipose tissue in Prader–Willi syndrome rescued by growth hormone treatment

ReferenceCitation: Eddiry S, Diene G, Molinas C, Salles J, Auriol FC, Gennero I, Bieth E, Skryabin BV, Rozhdestvensky TS, Burnett LC, Leibel RL, Tauber M, Salles JP. SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome. Genet Med. 2021 Sep;23(9):1664-1672. doi: 10.1038/s41436-021-01185-y. Epub 2021 May 26.

full_name: Sanaa Eddiry

given: Sanaa

full_name: Gwenaelle Diene

given: Gwenaelle

full_name: Catherine Molinas

given: Catherine

full_name: Juliette Salles

given: Juliette

family: Auriol

full_name: Françoise Conte Auriol

given: Françoise Conte

family: Gennero

title: SNORD116 and growth hormone therapy impact IGFBP7 in Prader–Willi syndrome

ReferenceCitation: Bieth E, Eddiry S, Gaston V, Lorenzini F, Buffet A, Conte Auriol F, Molinas C, Cailley D, Rooryck C, Arveiler B, Cavaillé J, Salles JP, Tauber M. Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi Syndrome. Eur J Hum Genet. 2015 Feb;23(2):252-5. doi: 10.1038/ejhg.2014.103. Epub 2014 Jun 11.

title: Highly restricted deletion of the SNORD116 region is implicated in Prader–Willi Syndrome

location_facility: CHU Toulouse Hôpital des Enfants Service d'endocrinologie - 330 ave de Grande Bretagne

location_facility: CHRU Lille Hôpital Jeanne de Flandre service de Pédiatrie

location_facility: CHU Strasbourg Hôpital Haute-Pierre - Avenue Molière

location_facility: CHU Brest Département de Pédiatrie - 5, ave Foch

location_facility: CHU Nice Hôpital Archet 2 - 151 route Saint Antoine de Ginestière

location_facility: CHU Montpellier Hôpital Arnaud de Villeneuve - 371 ave du doyen Gaston Giraud

location_facility: CHU Nantes Hôpital Mère Enfant Service de Pédiatrie

location_facility: CHU Lorient Hôpital du Scorff Pôle Femme Mère Enfant - Rue Guiguen

location_facility: CHU Rouen Hôpital Nicolle - 1, rue de Germont

location_facility: CHU Limoges Hôpital Mère Enfant Service Pédiatrie - 8, ave du Larrey

location_facility: CHU Grenoble Service de pédiatrie - BP 217

location_facility: CHU Lyon Hôpital Debrousse service Pédiatrie

location_facility: CHU La Rochelle Service de Pédiatrie - Rue du Dr Schweitzer

location_facility: CHU Dijon Service de pédiatrie - 2, Bd Maréchal de lattre de Tassigny

location_facility: AP-HP Hôpital Necker Enfants Malades Service d'endocrinologie pédiatrique - 149 route de Sèvres

location_facility: CHU Poitiers Service de Pédiatrie - Rue de la Miléterie

location_facility: CHU Reims Service de Pédiatrie - 47, rue Cognacq-Jay

location_facility: AP-HM Hôptal La Timone Service de Pédiatrie Mutidisciplinaire

location_facility: CHU Saint-Etienne Hôpital Nord Service de Pédiatrie

location_facility: CHU Bordeaux Hôpital Pellegrin Service endocrinologie de l'enfant - Place Amélie Raba Léon

location_facility: CHU Amiens Hôpital Nord Service Pédiatrie - Place Victor Pauchet

location_facility: CHRU Tours Centre de Pédiatrie Gatien de Clocheville

location_facility: CHU Besançon Hôpital Saint Jacques - 2 Place Saint Jacques


title: Phase II Trial Evaluating the Efficacy and Safety of Carboplatin Plus Pemetrexed in Human Immunodeficiency Virus Positive (HIV+) Patients With Stage III (Not Amenable to Radiation or Inoperable) or Stage IV Nonsquamous Non Small Cell Lung Cancer

acronym: CHIVA

summary: This is a phase II, multicenter, non-randomized, open-label study evaluating the combination of pemetrexed plus carboplatin in HIV-positive patients with lung cancer.

ReferenceCitation: Lavolé A, Chouaïd C, Baudrin L, Wislez M, Raguin G, Pialoux G, Girard PM, Milleron B, Cadranel J. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer. 2009 Sep;65(3):345-50. doi: 10.1016/j.lungcan.2008.11.018. Epub 2009 Jan 9.

lead_sponsor: Intergroupe Francophone de Cancerologie Thoracique

location_facility: Centre François Magendie - hôpital du Haut-Lévèque


title: Prospective, Multicentre, Observational Study

acronym: TCD

summary: Patients with mild to moderate traumatic brain injury (TBI) are at risk for secondary neurological deterioration. Their outcome within the first week after injury could be predicted by clinical signs, brain CT scan and transcranial doppler (TCD) on admission to the emergency room. The investigators aim to evaluate the diagnostic performance of TCD to screen patients presented with mild to moderate TBI and mild lesions on CT scan, i.e., Trauma Coma Data Bank, TCDB classification II. The principal outcome measure is the negative predictive value of TCD.

ReferenceCitation: Thornhill S, Teasdale GM, Murray GD, McEwen J, Roy CW, Penny KI. Disability in young people and adults one year after head injury: prospective cohort study. BMJ. 2000 Jun 17;320(7250):1631-5.

ReferenceCitation: Davis DP, Kene M, Vilke GM, Sise MJ, Kennedy F, Eastman AB, Velky T, Hoyt DB. Head-injured patients who "talk and die": the San Diego perspective. J Trauma. 2007 Feb;62(2):277-81.

ReferenceCitation: Livingston DH, Lavery RF, Passannante MR, Skurnick JH, Baker S, Fabian TC, Fry DE, Malangoni MA. Emergency department discharge of patients with a negative cranial computed tomography scan after minimal head injury. Ann Surg. 2000 Jul;232(1):126-32.

ReferenceCitation: Marshall LF, Marshall SB, Klauber MR, van Berkum Clark M, Eisenberg HM, Jane JA, et al. A new classification of head injury based on computerized tomography. J Neurosurg 1991; 75: S14-S20.

ReferenceCitation: Wardlaw JM, Easton VJ, Statham P. Which CT features help predict outcome after head injury? J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):188-92; discussion 151.

ReferenceCitation: Sifri ZC, Homnick AT, Vaynman A, Lavery R, Liao W, Mohr A, Hauser CJ, Manniker A, Livingston D. A prospective evaluation of the value of repeat cranial computed tomography in patients with minimal head injury and an intracranial bleed. J Trauma. 2006 Oct;61(4):862-7.

ReferenceCitation: af Geijerstam JL, Oredsson S, Britton M; OCTOPUS Study Investigators. Medical outcome after immediate computed tomography or admission for observation in patients with mild head injury: randomised controlled trial. BMJ. 2006 Sep 2;333(7566):465. Epub 2006 Aug 8.

ReferenceCitation: Stein SC, Burnett MG, Glick HA. Indications for CT scanning in mild traumatic brain injury: A cost-effectiveness study. J Trauma. 2006 Sep;61(3):558-66. Review. Erratum in: J Trauma. 2007 May;62(5):1309.

ReferenceCitation: White H, Venkatesh B. Applications of transcranial Doppler in the ICU: a review. Intensive Care Med. 2006 Jul;32(7):981-94. Epub 2006 May 10. Review.

ReferenceCitation: McQuire JC, Sutcliffe JC, Coats TJ. Early changes in middle cerebral artery blood flow velocity after head injury. J Neurosurg. 1998 Oct;89(4):526-32.

ReferenceCitation: Jaffres P, Brun J, Declety P, Bosson JL, Fauvage B, Schleiermacher A, Kaddour A, Anglade D, Jacquot C, Payen JF. Transcranial Doppler to detect on admission patients at risk for neurological deterioration following mild and moderate brain trauma. Intensive Care Med. 2005 Jun;31(6):785-90. Epub 2005 Apr 16.

location_facility:
Ch Saint Julien En Genevois
Ch Voiron
Ch Belley
CH Nantes
Ch Thonon Les Bains
Ch Chambery
Chu Edouard Herriot
CHRA Annecy
Ch Grasse
CHU Lyon
CHU Pierre Benite
Chu Nimes
Ch Briancon
CHU Grenoble
Ch Saint Jean de Maurienne
Hopitaux Du Pays Du Mont Blanc
CH Valence
CHU
Ch Cannes

intervention_type: Device


summary: The goal of this multicentric prospective randomized controlled clinical and economic study is to investigate the effectiveness and cost-utility of long-term continuous intraduodenal infusion of levodopa ( DUODOPA), compared to best medical treatment, on advanced and severe form of Parkinson's disease.

lead_sponsor: Poitiers University Hospital

location_facility:
Hôpital Henri Mondor
Chu Lille
Chu de Nice
Chu de Limoges
Chu de Toulouse
CH d'Aix en Provence
Chu de Rouen
Chu Amiens
Chu de Marseille
Chu Saint Etienne
Ch Saint Antoine
Chu de Nantes
Chu de Poitiers
Chu de Lyon
Chu de Rennes
Chu de Nimes
Ch La Pitie Salpetriere
Chu de Strasbourg
Chu Clermont-Ferrand
Chu Bordeaux


ReferenceCitation: Burgel PR, Le Gros V, Decuypère L, Bourdeix I, Perez T, Deslée G. Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2017 Jan 31;17(1):25. doi: 10.1186/s12890-017-0372-z.

family: Burgel

full_name: Pierre-Régis Burgel

given: Pierre-Régis

family: Le Gros

full_name: Vincent Le Gros

given: Vincent

family: Decuypère

full_name: Laurent Decuypère

given: Laurent

family: Bourdeix

full_name: Isabelle Bourdeix

given: Isabelle

family: Perez

full_name: Thierry Perez

given: Thierry

family: Deslée

full_name: Gaëtan Deslée

given: Gaëtan

journal_name: BMC Pulmonary Medicine

repository_normalized: HAL

evidence: oa repository (via pmcid lookup)

repositories:
HAL
PubMed Central

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

acronym: REVERBREZ

title: Study of the Predictive Value of Airway Obstruction Reversibility on the Effectiveness of Indacaterol (Onbrez® Breezhaler ®) 150 mcg Once Daily in Patients With Moderate to Severe COPD

summary: In this 5-months study, the response of patients to salbutamol at baseline will be compared with their response to treatment with indacaterol.


title: Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer

acronym: GRECCAR 5

summary: After rectal excision, the rate of anastomotic leak and abscess is higher than after colic surgery. In order to limit and avoid the risk of pelvic sepsis after rectal excision, a prophylactic pelvic drainage is usually used. If current data have confirmed the uselessness of drainage in colic surgery, the question stay in abeyance in rectal surgery. This practice had never been evaluated in patients with rectal excision and low anastomosis (patients with a high risk of pelvic sepsis)

primary_purpose: Prevention

lead_sponsor: University Hospital, Bordeaux

location_facility: Service de Chirurgie Générale et Digestive - Hôpital Saint-Antoine

location_facility: Service de Chirurgie Digestive - CHU de Nantes - Hôtel Dieu

location_facility: Service de Chirurgie Digestive - Hôpital Purpan - Pavillon Dieulafoy

location_facility: Service de Chirurgie Digestive et Générale - Brabois

location_facility: Service de Chirurgie Viscérale - CHU Pontchaillou

location_facility: Service de Chirurgie Générale et Digestive - Hôpital Beaujon

location_facility: Département de Chirurgie Oncologique - Institut Paoli Calmette

location_facility: Service de Chirurgie Digestive - Hôpital des Diaconnesses - La Croix Saint-Simon

location_facility: Service de Chirurgie Digestive - Hôpital Saint-André - CHU de Bordeaux

location_facility: Service de Chirurgie Digestive et Viscérale - CHU Timone

location_facility: Service de Chirurgie Digestive - Hôpital A. Michallon

location_facility: Service de Chirurgie Digestive - CHU Charles Nicolle

location_facility: Département de Chirurgie Oncologique - Centre Oscar Lambret

location_facility: Département de Chirurgie Oncologique - CRLC Val d'Aurelle


title: Hematologic Toxicity Observation of the TPF Medical Protocol. Description of the Impact of Febrile Neutropenia in Patients Who Receive the Chemotherapy of the TPF Medical Protocol in Head and Neck Cell Carcinoma

acronym: OTOHTPF

summary: The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).

lead_sponsor: Groupe Oncologie Radiotherapie Tete et Cou

location_facility:
Polyclinique de Bordeaux Nord
Centre Guillaume le Conquerant
Centre Antoine Lacassagne
Centre Eugene Marquis
Centre Oscar Lambret
Centre Hospitalier Bretonneau
Centre Hospitalier
Centre Jean Perrin
Institut Jean Godinot
Centre Hospitalier de Vendée
Clinique Armoricaine
Centre René Gauducheau
Institut Sainte Catherine
Centre Leon Berard
Centre Hospitalier Universitaire
Groupe Hospitalier Pitié Salpétrière


location_facility: Institut Cancérologie- CENTRE HOSPITALIER BREST

title: PHASE II STUDY Evaluating the Toxicity and Activity of the Combination Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over With Metastatic Breast Cancer Over Expressing HER2

summary:
GERICO 09/0907 is a Phase II multicentric trial evaluating the toxicity and activity of the combination of lapatinib and capecitabine in locally advanced or metastatic breast cancer over expressing HER2 for patients aged ≥ 70 who have failed after one line of chemotherapy in combination with trastuzumab.

Due to the minimal participation of older people in clinical trials, there is a lack of data to make evidence-based decisions regarding chemotherapy in this indication.

The study is designed to investigate whether elderly patients with locally advanced or metastatic breast cancer over-expressing HER2 could take advantage of the combination lapatinib and capecitabine in term of clinical benefit, and with no adverse effects and no detrimental impact on functional status (part of geriatric assessment).

The main objective is to assess clinical benefit (defined at 4 months as complete response, partial response or stable disease), safety and preserved geriatric independence (main objective is a "bi-criteria" or composite criteria).


acronym: ESOGIA

summary:
This is a phase III randomized multicenter study involving subjects over 70 years of age with non small-cell lung cancer of IV and a PS of 0, 1 or 2, who have not previously received chemotherapy. The aim is to validate the use of a simplified geriatric scale (SGS) as a screening tool. If the SGS results are normal, the patient will be treated with dual-agent therapy based on platinum (carboplatin + pemetrexed if the histology is non epidermoid, carboplatin + gemcitabin if the histology is epidermoid), with no further geriatric assessment. When the SGS reveals abnormalities, a comprehensive geriatric evaluation (CGE) will be used to define two subpopulations on Balducci's fragility scale, who will receive either monotherapy (docetaxel) or best supportive care.

The strategy based on the SGS will be compared with a treatment algorithm based on standard criteria (PS and age), with no specific geriatric assessment. The main endpoint is the time to treatment failure. The SGS is composed of the Charlson co-morbidity scale, functional assessment based on PS, Katz' ADL scale, Lawton's simplified IADL scale, simplified cognitive assessment with the mini-MMSE according to Schultz-Larsen, a geriatric depression scale (GDS 5), and screening for a geriatric syndrome defined by the existence of dementia, repeated falls, and urinary and fecal incontinence. The SGS will be validated by comparison with the CGE, that will be administered systematically at enrollment. All the SGS items are included in the CGE.

Secondary endpoints will be quality of life (measured with the LCSS and EuroQoL questionnaires), overall survival, the objective response rate, and toxicity. The investigators will also study the predictive power of nutritional indices such as the PINI and the Buzby score with respect to survival, the treatment response, and tolerability.

lead_sponsor: Rennes University Hospital

location_facility: Centre Hospitalier Général de la Fontonne Antibes

location_facility: Centre Hospitalier Universaitaire de Brest

location_facility: Centre Hospitalier Général Salon de Provence

location_facility: Centre Hospitalier De Villefranche sur Saone

location_facility: Centre Hospitalier Universitaire d'Angers


title: Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), "Vulnerable" or "Frail" , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)

summary:
The objective of this study is to evaluate the feasibility of two different chemotherapy protocols with adjusted doses for patients aged 75 and over who often have medical problems other than prostate cancer. Patient will receive Docetaxel either every 3 weeks or weekly. In both cases, chemotherapy is combined with prednisone. The protocol will be considered feasible when patient will receive 6 cycles of chemotherapy (1 cycle = 3 weeks).

Additionally to this primary objective, efficacy will also be evaluated for both protocols as well as tolerance to treatment, quality of life and evolution of geriatric data.

location_facility: Centre Hospitalier de La Region D'Annecy


title: National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)

summary: This study describes the elevation of CPK in patient treated for solid tumors by TKI

lead_sponsor: Centre Oscar Lambret

location_facility:
Hôpital Edouard Herriot
Centre Paul Papin
Centre Jean Perrin
Hôpital Jean Minjoz
Institut Curie
Centre Henri Becquerel
Centre Antoine Lacassagne
Hôpital Tenon - APHP
Institut Jean Godinot
Hôpital Saint-Louis - APHP
Centre Eugène Marquis
CHU Limoges
Centre Val d'Aurelle
CHU Robert Debré
Centre René Huguenin
Institut Claudius Régaud
CHU Bordeaux
Institut Paoli Calmettes
Institut Bergonié
Institut de Cancérologie de la Loire
Institut Gustave Roussy
Centre Léon Bérard
Centre François Baclesse
Centre Alexis Vautrin
Centre Oscar Lambret
Hôpital Cochin - APHP
Hôpital Henri Mondor - APHP


title: Cost-effectiveness of New Surgical Treatments for Haemorrhoidal Disease - Randomized Controlled Trial Comparing Transanal Doppler-guided Arterial Ligation With Mucopexy and Stapled Haemorrhoidopexy (Longo's Technique)

acronym: LIGALONGO

summary: This multicentre RCT aims to compare two surgical treatments of haemorrhoidal disease: doppler-guided arterial ligation with mucopexy (DGALM) and stapled haemorrhoidopexy according to Longo (SH). The hypothesis of the trial is that the DGALM is at a lesser risk and is more cost-effective than SH. With a large number of patients managed in more than 20 centres, we aim to demonstrate that DGALM has a lower morbidity than SH when treating haemorrhoidal disease. At a lower postoperative risk and a lower risk of sequelae, the DGALM would demonstrate to be cost-effective for health care system and attractive for patients.

ReferenceCitation: Woaye-Hune P, Hardouin JB, Lehur PA, Meurette G, Vanier A. Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported Outcomes. Health Qual Life Outcomes. 2020 May 27;18(1):156. doi: 10.1186/s12955-020-01398-w.

apc_source: openAPC

family: Woaye-Hune

full_name: Pascal Woaye-Hune

given: Pascal

family: Hardouin

full_name: Jean-Benoit Hardouin

given: Jean-Benoit

family: Lehur

full_name: Paul-Antoine Lehur

given: Paul-Antoine

family: Meurette

full_name: Guillaume Meurette

given: Guillaume

family: Vanier

full_name: Antoine Vanier

given: Antoine

journal_name: Health and Quality of Life Outcomes

ReferenceCitation: Venara A, Podevin J, Godeberge P, Redon Y, Barussaud ML, Sielezneff I, Queralto M, Bourbao C, Chiffoleau A, Lehur PA; LigaLongo Study Group. A comparison of surgical devices for grade II and III hemorrhoidal disease. Results from the LigaLongo Trial comparing transanal Doppler-guided hemorrhoidal artery ligation with mucopexy and circular stapled hemorrhoidopexy. Int J Colorectal Dis. 2018 Oct;33(10):1479-1483. doi: 10.1007/s00384-018-3093-8. Epub 2018 May 28.

family: Venara

full_name: Aurelien Venara

given: Aurelien

family: Podevin

full_name: Juliette Podevin

family: Godeberge

full_name: Philippe Godeberge

given: Philippe

family: Redon

full_name: Yann Redon

given: Yann

family: Barussaud

full_name: Marie-Line Barussaud

given: Marie-Line

family: Sielezneff

full_name: Igor Sielezneff

given: Igor

family: Queralto

full_name: Michel Queralto

given: Michel

family: Bourbao

full_name: Cecile Bourbao

given: Cecile

family: Chiffoleau

full_name: Anne Chiffoleau

given: Anne

full_name: Paul A Lehur

given: Paul A

journal_name: International Journal of Colorectal Disease

location_facility: Lille University Hospital "Claude Huriez"

location_facility: Marseille University Hospital "La Timone"

location_facility: Marseille University Hospital "Hôpital Nord"


ReferenceCitation: Baulac M, Coulbaut S, Doty P, McShea C, De Backer M, Bartolomei F, Vlaicu M. Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes. Epileptic Disord. 2017 Jun 1;19(2):186-194. doi: 10.1684/epd.2017.0907.

family: Baulac

full_name: Michel Baulac

family: Coulbaut

full_name: Safia Coulbaut

given: Safia

family: Doty

full_name: Pamela Doty

given: Pamela

family: McShea

full_name: Cindy McShea

given: Cindy

family: De Backer

full_name: Marc De Backer

given: Marc

family: Bartolomei

full_name: Fabrice Bartolomei

given: Fabrice

family: Vlaicu

full_name: Mihaela Vlaicu

given: Mihaela

journal_name: Epileptic Disorders

publisher: John Libbey Eurotext

publisher_dissemination: John Libbey Eurotext

publisher_group: John Libbey Eurotext

publisher_normalized: John Libbey Eurotext

lead_sponsor: UCB Pharma

acronym: SELF

title: A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses

summary:
To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of 400 mg/day, or to a clinically effective lower dose for an individual patient, improves the tolerability and safety of lacosamide (200 mg to 400 mg/d) as add-on treatment for patients with partial onset epilepsy.

Explanation of acronym: SELF = Safety Efficacy Lacosamide Flexibility


acronym: ISALP

location_facility: CHRU de Strasbourg - Hôpital de Hautepierre

location_facility: CHU de Bordeaux - Groupe Hospitalier Pellegrin

location_facility: APHP - Groupe Hospitalier Pitié-Salpetrière

location_facility: CHU de Montpellier - Hôpital Gui de Chauliac

location_facility: CHU de Nîmes - Hôpital Universitaire Carémeau

title: Evaluating the Performance of Isotopic Brain Imaging of Glucose Metabolism Via PET (18F-FDG) and Perfusion SPECT (99mTc-ECD) for the Diagnosis of Prodromal Stage Alzheimer's Disease

summary: The primary objective of this study is to characterize cerebral metabolism modifications using 18F-FDG PET technology and perfusion with 99MTC-ECD SPECT in patients with prodromal Alzheimer's Disease drawn from a high risk population. We also compare PET and SPECT imaging within this framework, and search for optimal diagnostic thresholds.


title: Computed Tomography Scan Versus Color Duplex Ultrasound for Surveillance of Endovascular Repair of Abdominal Aortic Aneurysm. A Prospective Multicenter Study

acronym: ESSEA

summary:
Cumulative radiation dose, cost, contrast induced nephrotoxicity and increased demand for computed tomography aortography (CTA) suggest that duplex ultrasonoraphy (DU) may be an alternative to CTA-based surveillance. The investigators compared CTA with DU during endovascular aneurysm repair (EVAR) follow-up.

Patients undergoing EVAR have radiological follow-up data entered in a prospectively multicenter database. The gold standard test for endoleak detection was CTA. DU interpretation was performed independently of CTA and vice versa.

ReferenceCitation: Jean-Baptiste E, Feugier P, Cruzel C, Sarlon-Bartoli G, Reix T, Steinmetz E, Chaufour X, Chavent B, Salomon du Mont L, Ejargue M, Maurel B, Spear R, Midy D, Thaveau F, Desgranges P, Rosset E, Hassen-Khodja R; Association Universitaire de Recherche en Chirurgie Vasculaire. Computed Tomography-Aortography Versus Color-Duplex Ultrasound for Surveillance of Endovascular Abdominal Aortic Aneurysm Repair: A Prospective Multicenter Diagnostic-Accuracy Study (the ESSEA Trial). Circ Cardiovasc Imaging. 2020 Jun;13(6):e009886. doi: 10.1161/CIRCIMAGING.119.009886. Epub 2020 Jun 8.

name: Service de Chirurgie Vasculaire, INSERM U1065, CHU de Nice, Université Côte D’Azur, Nice, France (E.J.-B., R.H.-K.).

family: Jean-Baptiste

full_name: Elixène Jean-Baptiste

given: Elixène

name: Service de Chirurgie Vasculaire, CHU Edouard Herriot, Université Claude Bernard Lyon1, Lyon, France (P.F.).

family: Feugier

full_name: Patrick Feugier

given: Patrick

name: Délégation à la Recherche Clinique et à l’innovation, CHU de Nice, Université Côte D’Azur, Nice, France (C.C.).

family: Cruzel

full_name: Coralie Cruzel

given: Coralie

name: C2VN, APHM, CHU Timone, Service de Chirurgie Vasculaire, Aix Marseille Université, Marseille, France (G.S.-B.).

family: Sarlon-Bartoli

full_name: Gabrielle Sarlon-Bartoli

given: Gabrielle

name: Service de Chirurgie Vasculaire, CHU Amiens-Picardie, Université de Picardie Jules Verne, Amiens, France (T.R.).

family: Reix

full_name: Thierry Reix

given: Thierry

name: Service de Chirurgie Vasculaire, CHU Dijon-Bourgogne, Université de Bourgogne, Dijon, France (E.S.).

family: Steinmetz

full_name: Eric Steinmetz

given: Eric

name: Service de Chirurgie Vasculaire et angiologie, CHU de Toulouse, Université Paul Sabatier, Toulouse, France (X.C.).

family: Chaufour

full_name: Xavier Chaufour

given: Xavier

name: Service de Chirurgie Cardio-Vasculaire, CHU de Saint-Etienne, Université Jean Monnet, Saint-Etienne, France (B.C.).

family: Chavent

full_name: Bertrand Chavent

given: Bertrand

name: Service de Chirurgie Vasculaire et Endovasculaire, CHU de Besançon, Université de Franche-Comté, Besançon, France (L.S.d.M.).

family: Salomon du Mont

full_name: Lucie Salomon du Mont

given: Lucie

name: AP-HM, Department of Vascular Surgery, University Hospital Nord, Aix-Marseille Université, Marseille, France (M.E.).

family: Ejargue

full_name: Meghann Ejargue

given: Meghann

name: CHU Nantes, l’institut du thorax, service de chirurgie vasculaire, Inserm-UN UMR-957, Nantes, France (B.M.).

family: Maurel

full_name: Blandine Maurel

given: Blandine

name: Service de Chirurgie Vasculaire, CHU de Grenoble, Université Grenoble-Alpes, Grenoble, France (R.S.).

family: Spear

full_name: Rafaelle Spear

given: Rafaelle

name: Service de Chirurgie Vasculaire, CHU de Bordeaux, Bordeaux, France (D.M.).

family: Midy

full_name: Dominique Midy

given: Dominique

name: Service de Chirurgie Vasculaire, CHU de Strasbourg, Strasbourg, France (F.T.).

family: Thaveau

full_name: Fabien Thaveau

given: Fabien

name: Service de Chirurgie Vasculaire, CHU Henri Mondor, Créteil, France (P.D.).

family: Desgranges

full_name: Pascal Desgranges

given: Pascal

name: Service de Chirurgie Vasculaire, CHU de Clermont-Ferrand, Université d’Auvergne, Clermont-Ferrand, France (E.R.).

family: Rosset

full_name: Eugenio Rosset

given: Eugenio

family: Hassen-Khodja

full_name: Réda Hassen-Khodja

given: Réda

family: Bureau

full_name: Pascale Bureau

given: Pascale

family: Ravoux

full_name: Mireille Ravoux

given: Mireille

family: Bozzetto

full_name: Catherine Bozzetto

given: Catherine

family: Sevestre-Pietri

full_name: Marie-Antoinette Sevestre-Pietri

given: Marie-Antoinette

family: Terriat

full_name: Béatrice Terriat

given: Béatrice

family: Favier

full_name: Claire Favier

given: Claire

lead_sponsor: Centre Hospitalier Universitaire de Nice

location_facility: CHU de Grenoble - Service de Chirurgie Vasculaire

location_facility: CHU de Caen - Service de Chirurgie Vasculaire

location_facility: CHU de Besançon - Service de Chirurgie Vasculaire

location_facility: CHU de St Etienne - Service de Chirurgie Vasculaire

location_facility: CHU d'Amiens - Service de Chirurgie Vasculaire

location_facility: CHU de Bordeaux - Service de Chirurgie Vasculaire

location_facility: CHU de Montpellier - Service de Chirurgie Vasculaire

location_facility: CHU de Toulouse - Service de Chirurgie Vasculaire

location_facility: CHU de Nice - Service de chirurgie vasculaire

location_facility: CHU de Nantes - Service de Chirurgie Vasculaire

location_facility: CHU de Rouen - Service de Chirurgie Vasculaire

location_facility: AP-HP Créteil - Service de chirurgie vasculaire

location_facility: CHRU Lille Service de Chirurgie Vasculaire

location_facility: CHU de Strasbourg - Service de Chirurgie Vasculaire

location_facility: APHM - Hôpital Nord - Service de Chirurgie Vasculaire

location_facility: AP-HP - Pitié Salpétrière - Service de Chirurgie Vasculaire

location_facility: CHU de Dijon - Service de Chirurgie Vasculaire

location_facility: CHU d'Angers - Service de Chirurgie Vasculaire

location_facility: CHU Clermont-ferrand - Service de Chirurgie Vasculaire


title: Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock

acronym: ABDO-MIX

summary: The purpose of this randomized, comparative, open and multi-centre study is to show that two sessions of hemoperfusion with Toraymyxin performed within maximum 36 hours after the surgery of a peritonitis by hollow organ perforation reduce the mortality in patients suffering from septic shock.

ReferenceCitation: Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandière M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015 Jun;41(6):975-84. doi: 10.1007/s00134-015-3751-z. Epub 2015 Apr 11.

family: Payen

full_name: Didier M. Payen

given: Didier M.

family: Guilhot

full_name: Joelle Guilhot

given: Joelle

family: Launey

full_name: Yoann Launey

given: Yoann

family: Lukaszewicz

full_name: Anne Claire Lukaszewicz

given: Anne Claire

family: Kaaki

full_name: Mahmoud Kaaki

given: Mahmoud

family: Veber

full_name: Benoit Veber

given: Benoit

family: Pottecher

full_name: Julien Pottecher

given: Julien

family: Joannes-Boyau

full_name: Olivier Joannes-Boyau

given: Olivier

family: Martin-Lefevre

full_name: Laurent Martin-Lefevre

given: Laurent

family: Jabaudon

full_name: Matthieu Jabaudon

given: Matthieu

family: Mimoz

full_name: Olivier Mimoz

family: Coudroy

full_name: Rémi Coudroy

given: Rémi

family: Ferrandière

full_name: Martine Ferrandière

given: Martine

family: Kipnis

full_name: Eric Kipnis

given: Eric

family: Vela

full_name: Carlos Vela

given: Carlos

family: Chevallier

full_name: Stéphanie Chevallier

given: Stéphanie

family: Mallat

full_name: Jihad Mallat

given: Jihad

family: Robert

full_name: René Robert

given: René

journal_name: Intensive Care Medicine

oa_colors: green hybrid

evidence: open (via page says license)

license: cc-by-nc

license_normalized: cc-by-nc

location_facility:
Strasbourg University Hospital
Roanne Hospital
Dieppe Hospital
Clermont-Ferrand University Hospital
Lariboisière University Hospital
Saint Jean Hospital
Poitiers University Hospital
Lille University Hospital
Rouen University Hospital
Limoges University Hospital
Tours University Hospital
Saint-Malo Hospital
Saint Louis Hospital
La Source Hospital
Vendée Hospital
Bordeaux University Hospital
Dr Schaffner Hospital
Pontchaillou University Hospital


title: Evaluation of Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer

acronym: GANEA 2

summary: GANEA 2 is a new trial based on patient treated for a large breast tumor with proven axillary involved nodes. Patients enrolled in this trial will have first an axillary sonography with fine needle punction in case of suspected nodes before NAC. This primary evaluation allow to determine two groups of patients : group 1 : patients with proven involved axillary nodes and group 2, patients without proven axillary involved nodes. Patients of group 1, the study group, will undergo SLNB and complete level I-II axillary lymphadenectomy. Patients of group 2 will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.

primary_purpose: Other

lead_sponsor: Institut Cancerologie de l'Ouest

location_facility:
Hôpital E. Herriot
Centre Paul Papin
Hôpital Tenon
Centre Jean Perrin
Institut Curie
Centre René Gauducheau
CHU
Clinique Lasagesse
CHU Brabois
Centgre René Becquerel
Hôpital Lariboisière
Centre Eugène Marquis
Centre René Huguenin
Institut Paoli Calmette
Institut Bergonié
Institut Gustave Roussy
Centre Léon Berard
Centre Alexis Vautrin
Centre Val d'aurelle
Centre Oscar Lambret
Hôpital Saint Louis
Centre Hospitalier
Hôpital Européen Georges Pompidou


title: Pelvic and Aortic-cava Lymphadenectomy Randomized Phase III for Advanced Ovarian Cancer

acronym: CARACO

summary: It is a multicenter randomized trial of superior cleaning compared the absence of dissection in stage III patients with optimal surgical resection without retroperitoneal lymph node palpable.

status: Suspended

location_facility:
Hopital
Centre Paul Papin
Centre Val d'Aurelle
Institut Cancerologie de l'Ouest
Hospital
Centre Jean Perrin
Hôpital des Diaconesses
Centre René Huguenin
Centre Paul Strauss
Institut Claudius Regaud
Clinique Sainte Thérèse
Institut Paoli Calmette
Clinique Mutualiste
Centre G F Leclerc
Hôpital Européen Georges Pompidou
Hôpital Bretonneau
Hôpital Lariboisière